MyoVista wavECG vs VisualDx
VisualDx sells to a clinician who wants an image-led differential. Elite costs $299.99 per year and Core, the education plan, $249.99 per year, both billed annually, and groups of two to five users or larger enterprises ask for a quote. The software ranks a differential from findings and patient context and compares images by skin tone and body site. The vendor states no FDA clearance, so a buyer who requires a cleared product cannot use it.
HeartSciences offers MyoVista Insights, which the vendor describes as a device-agnostic ECG management system for 12-lead data and third-party AI-ECG models. The vendor's footer says its AI-ECG products are not commercially available in the United States, and the company says it does not intend to commercialize the wavECG device without a cleared algorithm. That leaves HeartSciences without a buyer today, with no customers named and no public price.
Decision support · Reviewed November 2, 2026
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
VisualDx
by VisualDx · founded 1999
Differential diagnosis builder with 50,000+ clinical images across skin tones and body sites.
When to pick each one
MyoVista wavECG
- Vendor describes it as device-agnostic ECG management
- Hosts third-party AI-ECG models, vendor says
VisualDx
- Elite $299.99 per year, billed annually
- Image comparison by skin tone and body site
- Group quotes start at two users
Score
Each row shows points earned of points available under the published rubric.
MyoVista wavECG
31of 100
VisualDx
48of 100
| Dimension | MyoVista wavECG | VisualDx | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 6 / 10 | 0 / 10 | +6 |
| EHR integrations (count) | 1.7 / 5.6 | 0 / 5.6 | +1.7 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 1.9 / 4.8 | 0 / 4.8 | +1.9 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 0 / 21 | 14.7 / 21 | -14.7 |
| RCT / meta-analysis / systematic review | 0 / 9 | 9 / 9 | -9 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 1.3 / 2.5 | 2.5 / 2.5 | -1.2 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
VisualDx
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Core (education) | n/a | $249.99 | Shown as $39.99 or $20.83 per month, billed annually. Free trial length is not stated. Annual plans that auto-renew have a 30-day grace period for a full refund of the renewed fee. |
| Elite (clinicians) | n/a | $299.99 | Shown as $49.99 or $24.99 per month, billed annually. |
| Groups and Enterprise | n/a | n/a | Contact for pricing, including small groups of 2 to 5 users. |
Evidence
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
VisualDx
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
4 PubMed records name VisualDx.
- Early Perspectives on Utilization of a Clinical Decision Support Tool: A Mixed-Methods Study. (opens in new tab)
- Experiences, challenges and lessons while implementing a clinical decision support system in Botswana. (opens in new tab)
- Racial disparities in skin tone representation of dermatomyositis rashes: a systematic review. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | MyoVista wavECG | VisualDx |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Epic | Not specified |
| Founded | n/a | 1999 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.